| 摘要 |
<p>New carnitine derivatives of general formula (I) are described in racemic and/or optically active form, as well as the process for their preparation and their use as pharmaceutical anti-angina active ingredients for the treatment of ischaemic heart disease. A further subject of the invention described herein is a process for producing the (R)-carnitine enantiomer from (S)-carnitine (or vice versa), through the use of derivatives of general formula (I).</p> |
